Naringin alleviates intestinal mucosal injury in mice with intra-abdominal infection by inhibiting non-canonical pyroptosis through P2X7 receptor

• Published in: Lu jun jun yi da xue xue bao Vol. 46; no. 2; pp. 139 - 146
• Main Authors: MA Yuan, DUAN Qianwen, DONG Xupeng
• Format: Journal Article
• Language: Chinese
• Published: Editorial Office of Journal of Army Medical University 01.01.2024
• Subjects: abdominal infection; caspase11; intestinal mucosal injury; non-canonical; sepsis
• ISSN: 2097-0927
• DOI: 10.16016/j.2097-0927.202307058

Objective To investigate the therapeutic efficacy and underlying mechanism of naringin (Ng) for intestinal mucosal injury in mice with intra-abdominal infection (IAI). Methods A mouse IAI model was established by intraperitoneal injection (i.p.) of lipopolysaccharide (LPS). Sixty-four healthy male mice were randomly assigned to 4 groups (n=16): Control group (0.2 mL PBS), LPS group (LPS 10 mg/kg), Ng group (50 mg/kg Ng+10 mg/kg LPS), and BzATP group (5 mg/kg BzATP +50 mg/kg Ng+10 mg/kg LPS). Ng and BzATP were administered i.p. 1 h before modeling, while the Control group received an equivalent volume of PBS. At 24 h post-modeling, 6 mice from each group were randomly selected and sacrificed for ileum collection, and the histopathological changes in the ileal mucosa and Chiu's score were assessed using HE staining. Immunofluorescence assay was employed to investigate the expression and distribution of intestinal mucosal P2X7, pyroptosis effector protein GSDMD, and macrophage marker CD68. Western blotting was c